Table 2.
Anthropometric measurements and change in pubertal status in follow-up, a comparison of the groups
| Group 1 (n:60) | Group 2 (n: 21) | Group 3 (n:18) | ||||
|---|---|---|---|---|---|---|
| Visit 1-before pandemic | Visit 2-before pandemic | Visit 1-before pandemic | Visit 2-pandemic | Visit 1-pandemic | Visit 2-pandemic | |
| Chronological age (yr) | 8.4 | 8.8 | 8.1 | 8.6 | 7.63* | 7.9† |
| Duration between the two visits (yr) | - | 0.45 | - | 0.46 | - | 0.34 |
| BMI SDS | 0.67 | 0.59 | 0.24 | 0.48 | 0.29 | 0.13 |
| Height SDS | 0.71 | 0.8 | 0.89 | 1.2 | 0.98 | 0.87 |
| Delta BMI-SDS (median) | - | -0.02 | - | 0.21‡ | - | -0.06 |
| Delta height SDS (median) | - | 0.14 | - | 0.24 | - | 0.08 |
| Tanner stage (%) | ||||||
| T II | 61.7 | 41.7 | 71.4 | 38.1 | 66.7 | 27.8 |
| T III | 31.7 | 33.3 | 14.3 | 33.3 | 22.2 | 55.6 |
| T IV | 5 | 10 | 4.8 | 9.5 | 11.1 | 11.1 |
| T V | 1.7 | 5 | 4.8 | 4.8 | 0 | 0 |
| Change in pubertal stage during follow-up | ||||||
| No change (%) | - | 67% | - | 57% | - | 61% |
| + 1 stage (%) | - | 32% | - | 38% | - | 39% |
| + 2 stages (%) | - | 1% | - | 5% | - | 0 |
| GnRH analogue therapy in follow-up n (%) | - | 5(8)§ | - | 4(20) | - | 8(44) |
| Basal LH (median) (IU/L) | 0.1 | - | 0.17 | - | 0.25 | - |
| Peak LH at LHRH stimulation test (IU/L) | 5 | - | 8.2 | - | 5.6 | - |
| Basal estradiol (median)(pg/ml) | 19.5 | - | 16 | - | 21.5 | - |
| Uterine length (mm) | 35.5 | - | 32.5 | - | 38 | - |
| Ovarian volume (cm3) | 3 | - | 2.6 | - | 2.5 | - |
| Screen time (h/day) | - | - | 1.5 | 3 | 2.1 | 3.25 |
*p:0.013 (group 3 vs groups 1&2),†p:0.005 (group 3 vs groups 1&2),‡p:0.04 (group 2 vs groups 1&3),
§p:0.003 (group 1 vs groups 2&3